ArticlePituitary2017
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Article in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance.The Journal of clinical endocrinology and metabolism · 2026Article
- Review
- Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.European radiology · 2023Article
- Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma.Brain sciences · 2023Article
- Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.Pituitary · 2022Article
- High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens, Greece) · 2022Review
- Article
- Update on pituitary adenomas in the 2017 World Health Organization classification: innovations and perspectives.Hormones (Athens, Greece) · 2021Review
- Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives.Reviews in endocrine & metabolic disorders · 2020Review
- MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.Pituitary · 2019Article
- MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Pituitary · 2018Article
- Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKnowledge of biological behavior is crucial for clinical management of functioning pituitary macroadenomas. For recurrent cases unresponsive to standard treatment, temozolomide (TMZ) has been used as a therapeutic alternative. MGMT (O6-methyl-guanine-DNA methyltransferase) and MSH6 (mutS homolog 6) immunoexpression have been linked to the response to TMZ treatment and MGMT immunoexpression has been additionally linked to early recurrence of non-functioning pituitary adenomas. The aim of this study was to assess the prognostic value of MGMT and MSH6 immunoexpression for aggressive functioning pituitary adenomas.
methodsThe study cohort comprised a single center series of 76 patients who underwent an operation for functioning pituitary macroadenoma. We retrospectively compared 38 patients with postoperative persistent or recurrent disease with another set of 38 patients who were in endocrine remission.
resultsLow-to-moderate MGMT immunoexpression (<50%) was significantly more frequent in the group with persistent/recurrent disease than in cases of endocrine remission (66 vs. 21%, p < 0.001). Furthermore, adenomas with low-to-moderate MGMT immunoexpression were significantly more often recurrent (76 vs. 30%, p < 0.001) and invasive (64 vs. 28%, p = 0.002).
conclusionIn our series, low-to-moderate MGMT immunoexpression was the only marker that significantly correlated with surgical invasiveness and recurrence in functioning pituitary macroadenomas. Therefore, in the future, MGMT status may be considered an additional marker for understanding the biological behavior of pituitary adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.